The anti-embola medicine improves the condition of two coronary patients' third

More than half of a group of patients with severe California-based coronarys, Europe and Japan improved after receiving remdesiviri, prepared by the California-based biofarmacetics firm Gilead Science, reports the Daily Mail, broadcasts the news.net.

Originally developed as a treatment for Ebola, the drug has also been effective in the fight against coronarys, such as the acute acute respiratory syndrome (SARS), which is a cousin of the new virus.

At the same time, a test in China that is testing the drug on patients with slight symptoms of the virus was suspended because of the lack of qualified patients.

Currently, there is no drug approved for treating COVID-19, the virus-related disease.

At least five major studies are testing remdesivitri, and the company has also given them more than 1,700 patients on emergency grounds.

In the study, which was published in the New England Journal of Medicine on Friday, 53 patients between the ages of 23 and 82 were studied, all were hospitalised or in the U.S., Canada, Europe, or Japan, and 34 were sick to seek breathing vehicles.

They were given the medicine for 10 days or as long as it was tolerated.

After an average of 18 days, more than two thirds of patients, 36 patients, needed less oxygen support or respiratory vehicles.

About half the patients left the hospital.